47 completed, 28 recruiting, 18 unknown, 15 terminated. 73 Phase 1, 54 Phase 2, 5 Not applicable, 4 Phase 3, 3 Early Phase 1.
Follow B-Cell Lymphoma: new trials by email Literature Review of B-Cell Lymphoma trials Research Report on B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RPM Signals in Outpatient CAR T Therapy Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome | Not yet recruiting | Current Health | 125 | 2026-12-01 | 2026-10-20 | |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. bendamustine hydrochloride, Cyclophosphamide, Fludarabine - B-cell Lymphoma | Phase 2 | Recruiting | Swiss Cancer Institute | 92 | 2026-09-24 | 2026-10-27 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| Phase I Study of FXS0683 in the Treatment of Blood Tumors FXS0683 - B-Cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 228 | 2026-06-02 | 2026-10-14 |
| In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma SL1617 Injection - B-cell Lymphoma | Phase 1 | Recruiting | Chinese PLA General Hospital | 18 | 2026-06-01 | 2026-08-20 |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) LY4152199 - IV - Lymphoma, Non-Hodgkin, B-cell Lymphoma | Phase 1 | Recruiting | Eli Lilly and Company | 215 | 2026-05-28 | 2026-11-04 |
| Anti CD19 Gene Therapy for B-cell Lymphoma Anti-CD19 gene injection - B-cell Lymphoma | Not applicable | Recruiting | Anhui Provincial Hospital | 18 | 2026-03-20 | 2026-01-21 |
| Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123 - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Enrolling by invitation | AvenCell Therapeutics, Inc. | 178 | 2026-01-29 | 2026-03-16 | |
| Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma BAFF-R CAR-T cells - B-cell Lymphoma | Phase 1 | Recruiting | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 30 | 2026-01-01 | 2026-02-27 |
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Pirtobrutinib - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Eli Lilly and Company | 13 | 2025-08-07 | 2026-04-17 |
| A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma Glofitamab - B-cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-06-06 | 2025-09-17 | |
| Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma, Lymphoma Non-Hodgkin | Recruiting | Henry M. Jackson Foundation for the Advancement of Military Medicine | 300 | 2025-05-01 | 2026-09-03 | |
| Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies CAR-T - Multiple Myeloma, B-cell Lymphoma | Phase 1 | Recruiting | The Third Affiliated Hospital of Southern Medical University | 60 | 2025-01-15 | 2025-01-06 |
| A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies XS-04 tablet - B-cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 168 | 2025-01-14 | 2026-09-25 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma Blood assessment - B-cell Lymphoma, Hodgkin Lymphoma | Not applicable | Active not recruiting | Centre Henri Becquerel | 108 | 2024-12-24 | 2025-12-30 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL ATRA, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Rita Assi | 24 | 2024-11-18 | 2026-02-10 |
| Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma Triple-targeted CAR-T Therapy - B-cell Lymphoma | Phase 1 | Withdrawn | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2024-11-07 | 2026-05-06 |
Showing 20 of 127. Sign in to see all of them.
Lymphoma, B-Cell (127) · Lymphoma, Non-Hodgkin (30) · Lymphoma (22) · Lymphoma, Follicular (22) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Lymphoma, B-Cell, Marginal Zone (18) · Lymphoma, Mantle-Cell (18) · Burkitt Lymphoma (17) · Lymphoma, Large B-Cell, Diffuse (13) · Leukemia, B-Cell (11) · Hodgkin Disease (9) · Waldenstrom Macroglobulinemia (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Recurrence (8) · Leukemia, Myeloid, Acute (7)
Hemic and Lymphatic Diseases (127) · Immune System Diseases (127) · Immunoproliferative Disorders (127) · Lymphatic Diseases (127) · Lymphoproliferative Disorders (127) · Neoplasms by Histologic Type (127) · Neoplasms (122) · Lymphoma (105) · Lymphoma, Non-Hodgkin (97) · Hematologic Diseases (41) · Leukemia (35) · Leukemia, Lymphoid (32) · Pathological Conditions, Signs and Symptoms (32) · Pathologic Processes (31) · Disease Attributes (28)
Rituximab (22) · Cyclophosphamide (18) · fludarabine (15) · obinutuzumab (7) · Etoposide (5) · ibrutinib (5) · Lenalidomide (4) · Prednisone (4) · fludarabine phosphate (4) · glofitamab (4) · pirtobrutinib (4) · venetoclax (4) · Bendamustine Hydrochloride (3) · Bortezomib (3) · Doxorubicin (3)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Eli Lilly and Company (4) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3) · Hoffmann-La Roche (3) · Pharmacyclics LLC. (3) · The Lymphoma Academic Research Organisation (3) · CRISPR Therapeutics AG (2) · Memorial Sloan Kettering Cancer Center (2) · Nurix Therapeutics, Inc. (2) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · TG Therapeutics, Inc. (2) · University of Maryland, Baltimore (2) · Uppsala University (2) · AbbVie (1)
United States (62) · China (37) · France (19) · Australia (14) · Germany (10) · Italy (10) · United Kingdom (10) · Spain (8) · Poland (7) · Belgium (6) · Canada (6) · South Korea (6) · Switzerland (6) · Sweden (5) · Brazil (3)
Jae Park, MD (2) · Abraham Leung, MD (1) · Adam J Olszewski, MD (1) · Alain Rahmouni, Prof. (1) · Andrew Davies, Prof (1) · Annie Weaver, PhD (1) · Arturo Molina, MD (1) · Baijun Fang, Prof. (1) · Benjamin Kasenda, PD Dr. med. Dr. phil. (1) · Caitlin K Gribbin, M.D. (1)
PMID 23045577, PMID 23295790, PMID 23770158, PMID 24895339, PMID 25381051, PMID 26183076, PMID 26193343, PMID 26966027, PMID 27482888, PMID 27964867, PMID 28167659, PMID 30117142, PMID 30770362, PMID 31011207, PMID 33073216, PMID 33227125, PMID 33676628, PMID 33750072, PMID 34398557, PMID 34464155, PMID 34687939, PMID 34780125, PMID 34889384, PMID 35383885, PMID 35432352, PMID 35468680, PMID 35488407, PMID 35595730, PMID 35605184, PMID 35798714, PMID 35900694, PMID 36045296, PMID 36059523, PMID 36477110, PMID 36728217, PMID 37192437, PMID 37192741, PMID 37251628, PMID 37407001, PMID 37486616, PMID 37540566, PMID 37624619, PMID 37774014, PMID 37883795, PMID 38376944, PMID 38502198, PMID 38598516, PMID 38861666, PMID 39033770, PMID 39319495
2025 (3), 2017 (2), 2005 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), R01CA141303 (1)